Cargando…
The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor
Baloxavir marboxil (BXM) is an FDA-approved antiviral prodrug for the treatment of influenza A and B infection and postexposure prophylaxis. The active form, baloxavir acid (BXA), targets the cap-snatching endonuclease (PA) of the influenza virus polymerase complex. The nuclease activity delivers th...
Autores principales: | Todd, Brendan, Tchesnokov, Egor P., Götte, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065212/ https://www.ncbi.nlm.nih.gov/pubmed/33647314 http://dx.doi.org/10.1016/j.jbc.2021.100486 |
Ejemplares similares
-
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018) -
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018) -
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019) -
Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019) -
Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection
por: Ando, Yoshinori, et al.
Publicado: (2020)